Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.51 |
| ▸ | DRD2 | P14416 | 5/20 | 0.45 |
| ▸ | DRD3 | P35462 | 5/20 | 0.45 |
| ▸ | DRD1 | P21728 | 3/20 | 0.45 |
| ▸ | DRD5 | P21918 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19959005 | 0.79 | HRH3 (0.53) | HRH3DRD2DRD3DRD1DRD5 | |
| SCHEMBL14349615 | 0.76 | KDM4E (0.52) | HRH3ALDH1A1LMNAGAAMAPT | |
| SCHEMBL26972346 | 0.75 | HRH3 (0.49) | HRH3DRD2DRD3DRD1DRD5 | |
| SCHEMBL21421582 | 0.75 | HRH3 (0.49) | HRH3DRD2DRD3DRD1DRD5 | |
| SCHEMBL2733014 | 0.74 | SMN1; SMN2 (0.50) | ALDH1A1GAAMAPTSMN1; SMN2 | |
| SCHEMBL12412677 | 0.72 | HSD11B1 (0.48) | DRD2ALDH1A1LMNAMAPTMAPK1 | |
| SCHEMBL21419341 | 0.72 | KMT2A (0.49) | HRH3ALDH1A1LMNAGAAMAPT | |
| SCHEMBL21421763 | 0.72 | HRH3 (0.43) | HRH3DRD2DRD3DRD1DRD5 | |
| SCHEMBL14376046 | 0.71 | PPARA (0.53) | HRH3DRD2DRD3LMNAMAPT | |
| SCHEMBL12412701 | 0.71 | SMN1; SMN2 (0.56) | HRH3DRD2DRD3ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11173211-B2 | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20200129627-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200129627-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | HRH3 3690/4885DRD2 4522/4885DRD3 4621/4885 |
| US-11173211-B2 | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides | CRBN, ARAF, VHL | HRH3 3690/4885DRD2 4522/4885DRD3 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.